The FDA said one pivotal trial plus confirmatory evidence will become the default standard for approval of most new drugs. The shift could extend beyond rare diseases to common conditions affecting millions.
Fujifilm Biotechnologies has opened the UK's largest single-use biopharmaceutical CDMO facility in Teesside with a £400 million investment. The 110,000 sq ft facility features 19,000 liters of bioreactor capacity and will be operational in H1 2026. The expansion includes a new Bioprocess Innovation Centre that doubles the site's lab footprint.
New AI platforms are emerging to address rare disease diagnosis and epidemiology, as global costs reach up to $8.6 trillion annually affecting 300 million patients worldwide across more than 7,000 distinct conditions.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07573072 |
Characterization of the Methylation Profile of Stored Human Samples |
COMPLETED | |
| NCT06656247 |
Implementing Dynamic Consent for Rare Disease Patients |
NOT_YET_RECRUITING | |
| NCT01087320 |
Genome Medical Sequencing for Gene Discovery |
RECRUITING |
